Showing 2441-2450 of 3315 results for "".
- Sightview Appoints Tycene Fritcher as CEOhttps://modernod.com/news/sightview-appoints-tycene-fritcher-as-ceo/2482850/Ophthalmic Electronic health record (EHR) provider Sightview announced that Tycene Fritcher has been appointed Chief Executive Officer. Ms. Fritcher brings more than two decades of leadership experience in healthcare IT, including tenures at Nextech, Avizia, and Am
- SpliceBio Secures $135M Series B to Advance Gene Therapy for Stargardt Diseasehttps://modernod.com/news/splicebio-secures-135m-series-b-to-advance-gene-therapy-for-stargardt-disease/2482845/SpliceBio announced the closing of a $135 million Series B financing round to support the clinical advancement of SpliceBio’s lead gene therapy candidate, SB-007, for Stargardt disease. There are currently no approved treatments for the disease, which is
- Qlaris Bio Developing Fixed-Dose Combination Therapy for the Treatment of Glaucomahttps://modernod.com/news/qlaris-bio-developing-fixed-dose-combination-therapy-for-the-treatment-of-glaucoma/2482844/Qlaris Bio announced it is developing a novel preservative-free, fixed-dose combination therapy that combines the company’s lead program, QLS-111, and latanoprost. The fixed-dose combination (QLS-111-FDC) is being developed as a treatment for p
- Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nourish-and-blink-boost-lubricating-eye-drops-in-the-us/2482834/Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry e
- NASA Astronauts to Headline Heidelberg Engineering’s 2025 International Spectralis Symposiumhttps://modernod.com/news/nasa-astronauts-to-headline-heidelberg-engineerings-2025-international-spectralis-symposium/2482818/Heidelberg Engineering announced that NASA astronauts Warren Hoburg and Tyson Brunstetter, OD, PhD, will lead the keynote presentation at the company’s
- NIH Study: Experimental Drug May Help Treat Condition May Help Treat Diabetic Retinopathyhttps://modernod.com/news/nih-study-experimental-drug-may-help-treat-condition-may-help-treat-diabetic-retinopathy/2482805/A new National Institutes of Health (NIH)-funded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nu
- Bausch + Lomb Launches Zenlens CHROMA HOA in the UShttps://modernod.com/news/bausch-lomb-launches-zenlens-chroma-hoa-in-the-us/2482802/Bausch + Lomb announced the US launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos an
- The Alliance for Healthcare from the Eye Launches to Transform Disease Detectionhttps://modernod.com/news/the-alliance-for-healthcare-from-the-eye-launches-to-transform-disease-detection/2482801/A coalition of healthcare leaders announced the launch of the 'Alliance for Healthcare from the Eye (AHE)' at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City. AHE is a cross-sector initiative
- EyeCool Therapeutics Announces Positive Results from Pilot Study in Patients with Chronic Ocular Surface Pain (COSP)https://modernod.com/news/eyecool-therapeutics-announces-positive-results-from-pilot-study-in-patients-with-chronic-ocular-surface-pain-cosp/2482799/EyeCool Therapeutics announced positive clinical data from a double-masked, randomized controlled pilot study of 31 patients in Australia evaluating the safety and efficacy of its investigational device (ETX-4143) for the treatment of Chronic Ocular Surface Pain (COSP). T
- Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVOhttps://modernod.com/news/opus-genetics-announces-presentation-of-opgx-lca5-gene-therapy-data-at-arvo/2482782/Opus Genetics announced 1-year results from adult patients treated in the ongoing phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), taking place May 4